Published: January 2020 | Report Code: LS11991 | Available Format: PDF | Pages: 198
The gene therapy market revenue stood at $3,407.5 million in 2019, and the market is predicted to progress at a CAGR of 31.1% between 2020 and 2030. The increasing prevalence of chronic diseases, surging number of research and development (R&D) projects in this field, and positive results of the recently conducted clinical trials across the world are the major factors driving the growth of the market.
The in vivo category is predicted to lead the market for gene therapy in the coming years, under the type segment. This will be because this method eliminates the requirement for removing the cells from the patient’s body, manipulating them outside the body, and then returning them to their original place. Additionally, unlike the ex vivo method, it causes no harm to the host cells and, thus, does not disrupt their functioning.
In the forthcoming years, the viral category is predicted to exhibit the fastest growth in the market for gene therapy, under segmentation by vector type. This will be due to the fact that viral vectors are exhibiting high levels of genomic expression and incorporation in clinical trials. Moreover, viral vectors are more efficient than non-viral variants and are, thus, widely being adopted all over the world.
The oncology category generated the highest revenue in the gene therapy market in 2019, under the application segment. This is credited to the high incidence of cancer and the fact that around 60% of the currently ongoing clinical trials in the field of gene therapy are aimed at cancer treatment, because gene therapy is high selective in killing tumor cells.
Pharmaceutical and biotechnology companies contributed the highest revenue to the market from 2014 to 2019, under segmentation by end user. This was due to the existence of several industry players who outsourced the vector production process for expanding the application of gene therapy, so that it can be applied to many more diseases than presently.
North America held the largest share in the market in 2019, and this trend is expected to continue in the forthcoming years. This is ascribed to the increasing prevalence of rare diseases and cancer and presence of several leading industry players in the region. In addition, regulatory authorities in the region are rapidly approving gene therapy products, thereby fueling the expansion of the market.
One of the major trends currently being witnessed in the gene therapy market is the outsourcing of the manufacturing of gene therapy products by the leading industry players. They are outsourcing the production to contract manufacturing organizations (CMO) in order to improve their operational efficiency and productivity and attain reduced time-to-market and quality gains.
For example, Prevail Therapeutics Inc., which produces gene therapy products based on the adeno-associated-virus (AAV) for patients diagnosed with neurodegenerative diseases, announced in October 2019 that it has signed an agreement with Lonza for developing products that comply with good manufacturing practices (GMP). As per the agreement, Lonza will develop Prevail’s PR006 and PR001 gene therapies.
The growing prevalence of chronic diseases, such as cancer and various rare diseases, is one of the major factors driving the progress of the market. The reason behind this is that the currently available gene therapies can treat various rare diseases, especially those that are caused due to genetic problems, to some extent. For example, cancer-targeting therapies do not generate a demand for long-term transgene expression.
According to the American Cancer Society, in the U.S., the number of new cancer cases grew from 1,685,210 to 1,762,450 from 2016 to 2019. Similarly, the country witnessed a massive rise in cancer mortality, from 595,690 to 606,880 from 2016 to 2019. Issues such as this have propelled the expansion of the gene therapy market in the country and the world.
The growth of the gene therapy industry is being slightly hampered by the low production volume, high production costs, high capital requirements, and long lead times. To overcome these issues, the automation of the production process is becoming necessary, as this will drastically reduce the requirement for manual labor, variability in production, and the cost of the products. Additionally, the manufacturing and throughput efficiency can be augmented without affecting the purity of the active particles by enhancing the vector and cell technologies. Moreover, the optimization of therapy delivery systems would reduce the need for invasive intrathecal and intracellular injections and improve the management of blood, liver, immune system, eye, and spine diseases.
|Market Size by Segments||Type, Vector Type, Application, End User|
|Market Size of Geographies||U.S., Canada, Germany, France, Italy, Spain, U.K., Japan, China, India, South Korea, Brazil, Mexico, Saudi Arabia, South Africa|
|Market Players||Spark Therapeutics Inc., bluebird bio Inc., Orchard Therapeutics plc, Amgen Inc., REGENXBIO Inc., Thermo Fisher Scientific Inc., Applied Genetic Technologies Corporation, Pfizer Inc., Adverum Biotechnologies Inc., Novartis AG|
In recent years, the gene therapy market players have engaged in a number of collaborations and partnerships, to leverage each other’s expertise and technologies for mutual business prosperity.
For instance, Forty Seven Inc. and bluebird bio Inc. began a research collaboration in November 2019, for pursuing proof-of-concept clinical trials for Forty Seven Inc. Under the terms, the latter firm’s FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), which is a antibody-based conditioning regimen, will be tested together with lentiviral vector hematopoietic stem cell (LVV HSC), an ex vivo gene therapy platform developed by bluebird. The collaboration, aimed at a conditioning approach which would reduce toxicity, will be initially targeted at diseases that can be managed by transplanting autologous gene-modified blood-forming stem cells.
In the same vein, in August 2019, NIBRT and Allergan plc began a partnership to develop AAV-based gene therapies. The partnership focuses on establishing transfection/transduction conditions to minimize incorrect packaging events, optimizing the cell culture process of infectious AAV particles of various serotypes, and investigating sensitive analytical methods to differentiate between full and empty plastids.
The major players in the global gene therapy market are Spark Therapeutics Inc., bluebird bio Inc., Orchard Therapeutics plc, Amgen Inc., REGENXBIO Inc., Thermo Fisher Scientific Inc., Applied Genetic Technologies Corporation, Pfizer Inc., Adverum Biotechnologies Inc., and Novartis AG.
The gene therapy market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
Based on Type
Based on Vector Type
Based on Application
Based on End User
The gene therapy market generated revenue of $3,407.5 million in 2019.
The gene therapy industry will advance at a CAGR of 31.1% between 2020 and 2030.
The gene therapy market will exhibit the fastest growth in the APAC region from 2020 to 2030.
Gene therapy industry players are focusing on partnerships and collaborations in order to gain a stronger foothold in the market.
Vector type, type, application, end user, and region are the main segments of the gene therapy market.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws